Picture of Genexine logo

095700 Genexine Cashflow Statement

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Annual cashflow statement for Genexine, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
Standards:
IFRS
IFRS
IFRS
IFRS
IFRS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-16,50927,536-48,561-57,132-66,860
Depreciation
Amortisation
Non-Cash Items-22,413-62,25633,99030,85117,808
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-5,1539,109-1,473-18,3286,029
Change in Accounts Receivable
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-41,572-22,691-12,745-39,800-38,055
Capital Expenditures-5,082-24,116-57,007-31,779-7,379
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items6,719-40,27849,30229,864-26,904
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities1,637-64,394-7,704-1,915-34,283
Financing Cash Flow Items6,471-13,117
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities3,32873,35843,08731,63260,427
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-36,627-13,88122,584-9,853-11,910